论文部分内容阅读
目的:探讨阿奇霉素在治疗儿童支原体肺炎时的临床疗效与安全性。方法:将本院已确诊为支原体肺炎的128例住院患儿随机分为治疗组与对照组,治疗组每天静脉注射阿奇霉素10mg/kg,对照组每天静脉注射红霉素20mg/kg。总结比较两组患儿治疗临床有效率、平均住院天数、症状消失天数及不良反应发生率。结果:治疗组和对照组临床总有效率分别为98.44%,90.62%;平均住院天数分别为8.6天,12.3天;症状消失天数分别为7.2天,11.6天;不良反应发生率分别为12.5%,23.44%。结论:阿奇霉素在临床治疗小儿支原体肺炎方面疗效显著,安全可靠。与红霉素相比优势明显,临床推广价值高。
Objective: To investigate the clinical efficacy and safety of azithromycin in the treatment of children with mycoplasma pneumonia. Methods: A total of 128 inpatients with mycoplasma pneumonia who had been diagnosed as mycoplasmal pneumonia were randomly divided into treatment group and control group. The treatment group received intravenous azithromycin 10 mg / kg daily and the control group received daily intravenous erythromycin 20 mg / kg. The clinical efficacies, average days of hospitalization, disappearance of symptoms and incidence of adverse reactions were compared between the two groups. Results: The total effective rates of the treatment group and the control group were 98.44% and 90.62% respectively. The average hospitalization days were 8.6 days and 12.3 days respectively. The number of days of symptom disappearance was 7.2 days and 11.6 days respectively. The incidences of adverse reactions were 12.5% 23.44%. Conclusion: Azithromycin is effective and safe in the treatment of children with mycoplasma pneumonia. Compared with erythromycin obvious advantages, clinical promotion of high value.